87,555 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Purchased by Capital Fund Management S.A.

Capital Fund Management S.A. acquired a new stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 87,555 shares of the company's stock, valued at approximately $1,200,000. Capital Fund Management S.A. owned approximately 0.10% of Myriad Genetics at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of MYGN. KBC Group NV boosted its position in shares of Myriad Genetics by 132.8% in the 4th quarter. KBC Group NV now owns 5,845 shares of the company's stock worth $80,000 after buying an additional 3,334 shares in the last quarter. Inspire Advisors LLC raised its position in Myriad Genetics by 48.1% during the fourth quarter. Inspire Advisors LLC now owns 11,226 shares of the company's stock worth $154,000 after acquiring an additional 3,644 shares during the last quarter. E Fund Management Co. Ltd. purchased a new stake in shares of Myriad Genetics in the fourth quarter valued at about $161,000. Entropy Technologies LP acquired a new stake in shares of Myriad Genetics in the fourth quarter valued at approximately $178,000. Finally, Polymer Capital Management US LLC purchased a new position in shares of Myriad Genetics during the 4th quarter worth approximately $179,000. 99.02% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MYGN has been the topic of several recent research reports. Scotiabank reduced their price objective on Myriad Genetics from $24.00 to $20.00 and set a "sector outperform" rating on the stock in a research report on Tuesday, April 1st. The Goldman Sachs Group reduced their target price on Myriad Genetics from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday. Craig Hallum assumed coverage on shares of Myriad Genetics in a research note on Wednesday, February 12th. They issued a "buy" rating and a $29.00 target price on the stock. UBS Group lowered their price objective on shares of Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating for the company in a research report on Tuesday, February 25th. Finally, Guggenheim downgraded Myriad Genetics from a "buy" rating to a "neutral" rating in a report on Wednesday, April 9th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Myriad Genetics presently has an average rating of "Hold" and a consensus target price of $20.61.

Myriad Genetics Stock Down 3.4 %

NASDAQ:MYGN traded down $0.27 during mid-day trading on Friday, reaching $7.64. The stock had a trading volume of 1,606,449 shares, compared to its average volume of 909,000. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. The stock has a market cap of $704.19 million, a P/E ratio of -5.88 and a beta of 1.87. Myriad Genetics, Inc. has a fifty-two week low of $7.35 and a fifty-two week high of $29.30. The business's 50 day moving average is $10.24 and its 200 day moving average is $14.41.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The business had revenue of $210.60 million for the quarter, compared to analyst estimates of $210.35 million. During the same period in the previous year, the company earned ($0.12) earnings per share. As a group, sell-side analysts predict that Myriad Genetics, Inc. will post -0.3 earnings per share for the current year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.